The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease

Clinical Neuropharmacology

Volumn 21, Issue 3, 1998, Pages 169-175

  Schrag, A E ^a   Brooks, D J ^b   Brunt, E ^c   Fuell, D ^d   Korczyn, A ^e   Poewe, W ^f   Quinn, N P ^a   Rascol, O ^g   Stocchi, F ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d GLAXOSMITHKLINE   (United Kingdom)

^e TEL AVIV UNIVERSITY   (Israel)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g INSERM   (France)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adverse experiences; Dopamine agonist; Parkinson's disease; Ropinirole; Tolerability; Treatment

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; ROPINIROLE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; SOMNOLENCE; VERTIGO; VOMITING;

EID: 0031864764     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney Multicentre Study of Parkinson's Disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopacarbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-10.
2. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised, controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
3. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC 12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95:2458-64.
4. Karch FE, Lasagna L. Adverse drug reactions: a critical review. JAMA 1975;234:1236-41.
5. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5HT3 receptor antagonist. Neurology 1995;7:1305-8.
6. McHale DM, Sage JI. Hallucinations and confusion after pergolide withdrawal. Clin Neuropharmacol 1988;11:545-8.
7. Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson's disease. Neurology 1994;44(suppl 10):S1-S52.
8. Corsini GU, Del Zompo M, Manconi S, Piccardi MP, Onali PL, Mangoni A. Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sci 1977;20:1613-18.
9. Stern GM, Lees AJ. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease. Adv Neurol 1983; 37:17-21.
10. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology 1985;35:296-9.
11. Olanow CW, Alberts MJ. Double-blind, controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease. Adv Neurol 1987;45:555-60.
12. Quinn NP. Antiparkinsonian drugs today. Drugs 1984;28:236-62.
13. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30:613-16.
14. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergotderivative, cabergoline. Eur Respir J 1992;5:263-5.